Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤2.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Clone 3.9 preferentially binds the activated form of CD11c, is specific for the I domain of CD11c, and is able to partially block the binding of CD11c and ICAM-4. 3.9 binding is divalent cation dependent¹². While analyzing blood, it is best to use heparin as the anti-coagulant and not EDTA. Since the ability of clone 3.9 to bind to its target is divalent cation dependent, the usage of EDTA as an anti-coagulant may be detrimental to staining due to its chelating properties.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁴, and functional assays^5,6. The LEAF? purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 301616). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 301632) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W, et al. 1989. Leucocyte Typing IV Oxford University Press. New York.
3. McMichael A, et al. Eds. 1987. Leucocyte Typing III Oxford University Press. New York.
4. Vainer B, et al. 2000. Am. J. Surg. Pathol. 24:1115. (IHC)
5. Ottonello L, et al. 1999. Blood 93:3505.
6. Metelitsa LS, et al. 2002. Blood 99:4166.
7. Sadhu C, et al. 2007. J. Leukoc. Biol. doi:10.1189/jlb.1106680. PubMed
8. Ihanus E, et al. 2007. Blood 109:802-810.
9. Gurer C, et al. 2008. Blood 112:1231. PubMed
10. Asai A, et al. 2009. J. Lipid Res. 50:95. PubMed
11. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
12. Sadhu C, et al. 2008. J. Immunoass. Immunoch. 29:42. (FC)

1. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
2. Melo-Gonzalez F, et al. 2018. J Biol Chem. 293:8543. PubMed
3. Ortiz AM, et al. 2018. Nat Med. 24:1313. PubMed
4. Korn MA, et al. 2020. J Immunol. 205:2595. PubMed
5. Gurer C, et al. 2008. Blood. 112:1231. PubMed
6. Santos R, et al. 2017. Nat Commun. . 10.1038/s41467-017-01760-5. PubMed
7. Sadhu C, et al. 2007. J Leukoc Biol . 81:1395. PubMed
8. Kremenovic M, et al. 2020. Cancers (Basel). 12:. PubMed
9. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
10. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
11. Gonzalez VD, et al. 2021. Cell Reports. 36(9):109632. PubMed
12. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
13. Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed
14. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
15. Lukácsi S, et al. 2020. PLoS One. 15:e0232432. PubMed
16. Baskar R, et al. 2022. Cell Rep Methods. 2:. PubMed
17. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
18. Roussel M, et al. 2021. Cell Reports Medicine. 2(6):100291. PubMed
19. Asai A, et al. 2009. J Lipid Res. 83:4365. PubMed
20. Kato M, et al. 2021. PLoS One. 16:e0252116. PubMed
21. Delgado-Gonzalez A, et al. 2022. STAR Protoc. 3:101425. PubMed
22. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
23. Martin E, et al. 2020. JCI Insight. :5. PubMed

Myeloid, dendritic cells, NK cells, B cells and T cell subsets

1. Petty H. 1996. Immunol. Today 17:209.
2. Springer T. 1994. Cell 76:301.
3. Ihanus E, et al. 2007. Blood 109:802-810.